These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25361624)

  • 1. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Auchus RJ; Yu MK; Nguyen S; Mundle SD
    Oncologist; 2014 Dec; 19(12):1231-40. PubMed ID: 25361624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
    Ma H; Zhu G; Wan B; Wu PJ; Wang JY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Romero-Laorden N; Lozano R; Jayaram A; López-Campos F; Saez MI; Montesa A; Gutierrez-Pecharoman A; Villatoro R; Herrera B; Correa R; Rosero A; Pacheco MI; Garcés T; Cendón Y; Nombela MP; Van de Poll F; Grau G; Rivera L; López PP; Cruz JJ; Lorente D; Attard G; Castro E; Olmos D
    Br J Cancer; 2018 Oct; 119(9):1052-1059. PubMed ID: 30131546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
    Lorente D; Omlin A; Ferraldeschi R; Pezaro C; Perez R; Mateo J; Altavilla A; Zafeirou Z; Tunariu N; Parker C; Dearnaley D; Gillessen S; de Bono J; Attard G
    Br J Cancer; 2014 Dec; 111(12):2248-53. PubMed ID: 25314055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
    Gill D; Gaston D; Bailey E; Hahn A; Gupta S; Batten J; Alex A; Boucher K; Stenehjem D; Agarwal N
    Clin Genitourin Cancer; 2017 Aug; 15(4):e599-e602. PubMed ID: 28131750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
    Bertaglia V; Tucci M; Vignani F; Buttigliero C; Aroasio E; Berruti A; Scagliotti GV; DI Maio M
    Minerva Urol Nefrol; 2017 Aug; 69(4):349-358. PubMed ID: 28008755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
    Lin GW; Li GX; Dai B; Ye DW; Kong YY; Wang Y; Shen YJ
    Asian J Androl; 2019; 21(2):131-136. PubMed ID: 30560837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
    Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study.
    Attard G; Merseburger AS; Arlt W; Sternberg CN; Feyerabend S; Berruti A; Joniau S; Géczi L; Lefresne F; Lahaye M; Shelby FN; Pissart G; Chua S; Jones RJ; Tombal B
    JAMA Oncol; 2019 Aug; 5(8):1159-1167. PubMed ID: 31246234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
    McKay RR; Werner L; Jacobus SJ; Jones A; Mostaghel EA; Marck BT; Choudhury AD; Pomerantz MM; Sweeney CJ; Slovin SF; Morris MJ; Kantoff PW; Taplin ME
    Cancer; 2019 Feb; 125(4):524-532. PubMed ID: 30427533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Liao D; Lei H; Bai S; Peng G; Ai J; Yang L
    Urol Oncol; 2021 Nov; 39(11):754-763. PubMed ID: 34330654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.